Skip to content
Search

Latest Stories

RPS Scotland publishes policy document on pharmacy's role in reducing drug harms

The Royal Pharmaceutical Society has published a policy document on pharmacy’s role in reducing drug harms and preventing drug deaths in Scotland.

It highlights areas where pharmacy can contribute effectively to the treatment and prevention of drug harms and makes recommendations for how improvements can be achieved.


The document makes 14 recommendations including:

  • Naloxone must be available from every community pharmacy and staff trained to use it.
  • All pharmacists should have access to shared patient records and clear communication pathways with other health care professionals involved in the care of people who use drugs.
  • Regulated Supervised Drug Consumption Rooms (SDCRs) should be introduced and use of Heroin Assisted Treatment (HAT) should be expanded as treatment options with pharmacy input from the start.

RPS England and Wales teams were also working on developing the policy for their respective countries.

Laura Wilson, RPS Scotland policy and practice lead, said: “It’s concerning that drug related deaths and hospital admissions continue to rise in Scotland.  Many of these deaths are preventable.

"Pharmacists, and pharmacy teams, already play a big role in supporting and providing treatment to people who use drugs, as well as offering harm reduction services and advice. The RPS wants to build on this fantastic work by enabling them to do even more to reduce harm from drugs.

“We are calling on the Scottish government, pharmacy organisations, contractors and members of the profession to work together to reduce harm from drugs and improve the health of people who use drugs. We are also asking for significant resource, expertise and finance to be made available.

“Scotland needs to take action to reduce its high level of drug deaths, and pharmacy is well placed to play a critical role within this.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less